Welcome to our dedicated page for Sharps Technology SEC filings (Ticker: STSSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sharps Technology Inc. (STSSW) SEC filings page aggregates regulatory documents for Sharps Technology, Inc., a Nevada corporation whose common stock trades on Nasdaq under the symbol STSS. These filings provide detailed insight into the company’s medical device and pharmaceutical packaging activities, its Solana-focused digital asset treasury strategy, and the capital markets transactions that support both areas. Investors analyzing STSSW, which represents warrants linked to Sharps Technology’s common stock, can use these filings to understand the underlying corporate structure and key contractual arrangements.
Form 8-K current reports disclosed by the company describe material definitive agreements, including securities purchase agreements for private placements of common stock, pre-funded warrants, and stapled warrants. These documents explain how Sharps Technology raised funds to acquire SOL, the native asset of the Solana blockchain, and to establish Solana treasury operations, as well as the terms of registration rights agreements, warrant amendments, and at-the-market offering arrangements. Additional 8-K disclosures outline strategic advisor and consulting agreements connected to the company’s crypto technology and treasury activities.
Definitive proxy statements on Schedule 14A (DEF 14A) offer further context on governance and shareholder approvals. These filings cover items such as the election of directors, approval of equity incentive plans, increases in authorized common stock, and special meeting proposals to approve share issuances upon exercise of pre-funded and stapled warrants, including those associated with cryptocurrency-related financings and strategic advisor warrants. Together, these materials document how Sharps Technology structures and seeks stockholder approval for key elements of its financing and treasury strategy.
On this page, users can access these SEC filings as they become available through EDGAR, and can use AI-powered tools to summarize complex documents such as proxy statements and current reports. This helps readers quickly identify provisions related to warrant terms, share issuance approvals, treasury strategy disclosures, and advisory and consulting arrangements that are relevant when evaluating Sharps Technology and securities tied to it, such as STSSW.
Sharps Technology Inc. filed a preliminary proxy statement for a special meeting addressing several proposals. Shareholders are asked to elect Annemarie Tierney as a director to serve until the 2026 annual meeting. The company seeks approval under Nasdaq Listing Rule 5635(a) to issue unspecified numbers of common shares upon the exercise of multiple warrant arrangements, including "Cryptocurrency Warrants," "Strategic Advisor Warrants," pre-funded warrants and stapled warrants; the exact share amounts are redacted or shown as placeholders. Other agenda items include adjournment and transacting other proper business at the special meeting. The filing lists named officers and directors including Paul K. Danner (Executive Chairman and Principal Executive Officer), Andrew R. Crescenzo (CFO), and Yuwen (Alice) Zhang (Chief Investment Officer and Director). Several sections and numeric details appear incomplete or redacted in the provided excerpt.
Sharps Technology, Inc. entered into a Controlled Equity Offering Sales Agreement allowing it to sell, from time to time, up to $236,605,575 of its common stock through at-the-market offerings. Cantor Fitzgerald & Co. will act as principal and sole designated sales agent, with Aegis Capital Corp. also named as an agent, and will receive a 3.0% commission on gross proceeds from each sale. The company is not obligated to sell any shares and may suspend or terminate the program at any time. Any shares sold will be issued under existing shelf registration statements on Form S-3 and a prospectus supplement dated September 2, 2025.
Sharps Technology, Inc. is registering an at-the-market program to sell up to $236,605,575 of common stock through Cantor Fitzgerald and Aegis. Shares may be issued from time to time on Nasdaq under symbol STSS at prevailing prices, with a 3% sales commission to the agents.
The company plans to use any proceeds for general corporate purposes and, importantly, to pursue a new Solana (SOL)-focused digital asset treasury strategy, including SOL acquisitions and staking. Recent PIPE financings using cash and SOL, large warrant packages, and new leadership hires support this shift, but also introduce substantial dilution risk and exposure to highly volatile cryptocurrency markets.
Sharps Technology Inc. reported a material event describing issuance mechanics for warrants tied to a transaction: Strategic Advisor Warrants equal to 10% of the combined Cash Shares and Pre-Funded Warrant Shares, and upon exercise of each Stapled Warrant the Strategic Advisor receives additional warrants equal to 10% of the Stapled Warrant Shares exercised. The Strategic Advisor Warrants allow purchase of Common Stock (referred to as Strategic Advisor Warrant Shares). The filing discloses that Sol Markets, which is controlled by James Zhang, is related by family to the company through Alice Zhang, the company’s Chief Investment Officer and a Director. A company website link is provided.
Sharps Technology Inc. (STSS/STSSW) director Timothy James Ruemler reported four separate sales of company common stock on 08/27/2025, each for 5,000 shares at prices of $16.575, $16.54, $17.0922 and $16.75. After these transactions his beneficial ownership fell from 35,218 shares to 20,218 shares as shown on the form. The filing includes an explanatory note stating the shares were sold inadvertently and that Mr. Ruemler has tendered $90,600 to the company to cover short-swing profits. The Form 4 is signed and dated 08/28/2025.
Sharps Technology Inc. director Timothy Ruemler reported a series of open-market purchases totaling 40,000 shares of common stock on August 25, 2025, at prices ranging from $9.60 to $12.50, bringing his directly held stake to 40,218 shares.
He also received an option to buy 80,000 additional shares at an exercise price of $6.41 per share, granted under the company’s 2025 Equity Incentive Plan. This option becomes fully vested and exercisable on May 22, 2026 and expires on August 22, 2035.
Jason L. Monroe, a director of Sharps Technology Inc. (STSS), was granted an option to purchase 80,000 shares on 08/22/2025 with an exercise price of $6.41 per share. The option was granted under the company’s 2025 Equity Incentive Plan and will become 100% vested and exercisable on May 22, 2026. The Form 4 was signed by Mr. Monroe on 08/26/2025.
Andrew R. Crescenzo, who serves as Chief Financial Officer and a director of Sharps Technology Inc., was granted an option to purchase 40,000 shares on 08/22/2025 at an exercise price of $6.41 per share under the company's 2025 Equity Incentive Plan. The option is shown as directly beneficially owned for 40,000 shares following the grant and will become 100% vested and exercisable on May 22, 2026. The Form 4 was signed by Mr. Crescenzo on 08/26/2025. The filing lists the issuer as Sharps Technology Inc. (STSS).
Robert M. Hayes, a director of Sharps Technology Inc. (ticker shown as STSS), reported a securities transaction on a Form 4. The filing records an option (right to buy) for 100,000 shares with a price of $6.41. The transaction line shows the option entry dated 08/22/2025 and indicates the shares were acquired (code A) and are held directly. The filing notes the grant was made under the Company’s 2025 Equity Incentive Plan and that the option will be 100% vested as of the issuance date. The form includes an earliest-transaction date of 12/04/2024 and a signature dated 08/26/2025.
The reporting person, Soren Bo Christiansen, a director of Sharps Technology Inc. (STSS), was granted an option to purchase 80,000 shares on 08/22/2025 at an exercise price of $6.41 per share under the company's 2025 Equity Incentive Plan. The option will become 100% vested and exercisable on May 22, 2026. Following the grant the reporting person beneficially owns 80,000 shares/options as reported.